ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2236

Relation Between Sociodemographic Factors and Hand Function in Patients with Early Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2007

Relationship Between Gout Flare Burden and Patient-Reported Outcome Following Allopurinol Initiation

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2127

Relationship Between Serum Uric Acid and Trabecular Bone Score (TBS) in Healthy Population

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 2230

Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2092

Remote-Delivered Tai Chi and Gut Microbiota in Osteoarthritis: A Randomized Mechanistic Trial

Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2364

Reporting Mental Health and Associated Disorders from Trials of Bimekizumab in Patients with Active Axial Spondyloarthritis and Psoriatic Arthritis

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1790

Response Gene to Complement-32 Expression Is Upregulated in Lupus T Cells and Promotes Th17 Differentiation

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2122

Rheum for Improvement: Screening and Treatment of Glucocorticoid Induced Osteoporosis

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 2004

Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center

Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 2149

Rheumatoid Arthritis: Patient’s Voice First! An Original Approach Based on Infodemiology Using Social Media Content – Results from the PRIMA Study

Patient Outcomes, Preferences, & Attitudes Poster III

10:30AM-12:30PM: Abstract Number: L11

Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification

(L01–L14) Late-Breaking Posters

10:30AM-12:30PM: Abstract Number: 2151

Rheumatology on Reddit: A Descriptive Analysis

Patient Outcomes, Preferences, & Attitudes Poster III

10:30AM-12:30PM: Abstract Number: 2458

Risk Factors for Progression of Interstitial Lung Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2261

Risk of Cervical Intraepithelial Neoplasia During Janus Kinase (JAK) Inhibitor Treatment in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study

RA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2009

Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].